FindTrial
Sign In

LTP001

DRUG5 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Idiopathic Pulmonary FibrosisIdiopathic pulmonary fibrosisPart A: Healthy volunteers (Part A is not applicable to the EU; for information only) Part B: pulmonary arterial hypertensionPulmonary Arterial Hypertension

Phase 1

A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of LTP001 in healthy adult participants (Part A) and to evaluate the efficacy and safety of LTP001 for the treatment of participants with pulmonary arterial hypertension (Part B)
RecruitingCTIS2024-513613-12-00
Novartis Pharma AGPart A: Healthy volunteers (Part A is not applicable to the EU; for information only) Part B: pulmonary arterial hypertension
Start: 2025-09-18Target: 68Updated: 2026-01-07

Phase 2

Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension
TerminatedNCT05135000
Novartis PharmaceuticalsPulmonary Arterial Hypertension
Start: 2022-06-30End: 2024-04-25Updated: 2026-01-13
To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF
TerminatedNCT05497284
Novartis PharmaceuticalsIdiopathic Pulmonary Fibrosis
Start: 2022-11-10End: 2024-09-26Updated: 2026-01-13
Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants
TerminatedNCT05764265
Novartis PharmaceuticalsPulmonary Arterial Hypertension
Start: 2023-03-27End: 2024-05-14Updated: 2026-01-27
A participant - and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in patients with idiopathic pulmonary fibrosis
CompletedCTIS2023-508729-28-00
Novartis Pharma AGIdiopathic pulmonary fibrosis
Start: 2023-04-25End: 2024-09-26Target: 36Updated: 2024-03-18